SUBCUTANEOUS DRUGS IN ONCOLOGY- MAKE A DIFFERENCE IN THE TREATMENT? SYSTEMATIC REVIEW FROM DIFFERENT ANALYTICAL PERSPECTIVES
Author(s)
Medina Torres YA1, Gamboa Garay OA1, Moreno-Silva NA2, Díaz-Toro YR2
1Instituto para la Evaluación de la Calidad y Atención en Salud-IECAS, Bogotá, Colombia, 2Productos Roche S.A. Colombia, Bogotá, Colombia
OBJECTIVES: Compare time and economic benefits of the biotechnological subcutaneous (SC) drugs versus intravenous (IV) drugs in oncology. METHODS: A search of systematic reviews of economic literature, observational and economic studies, official or public policy documents of drug regulatory agencies of reference for Colombia, and INAHTA’s Health Technology Agencies, was carried out. The population was adults who required an IV treatment in room, also available as SC formulation. The databases Medline, Embase, Econlit and HTA were consulted. The quality of the evidence was evaluated with QHES and AMSTAR. Measures of central tendency and qualitative analysis were used in the final analysis. The third payer, insurer, provider and patient perspectives were considered. RESULTS: CONCLUSIONS: The SC administration of biotechnological drugs in Oncology is an efficient choice for the use of resources in health, providing a better quality of life to the patients, without affecting the safety and effectiveness of the treatments. Also is preferred by patients, reduces the direct and indirect costs, optimizes the productivity of professionals in health and allows a greater availability of infusion rooms. A holistic view of the health technologies from different perspectives is important for evidence-based decision-making in health.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN301
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology